This article needs additional citations for verification. (March 2020) |
The topic of this article may not meet Wikipedia's notability guidelines for companies and organizations. (November 2024) |
EyePoint Pharmaceuticals Inc. (formerly pSivida Corporation) is a Watertown, Massachusetts company specialising in the application of microelectromechanical systems (MEMS) and nanotechnology to drug delivery.
| Formerly | pSivida Corp. |
|---|---|
| Company type | Public company |
| Nasdaq: EYPT ASX: PVA FWB: PV3 | |
| Industry | Pharmaceuticals |
| Headquarters | , |
Number of locations | 2 |
| Products | Iluvien |
| Website | www |
pSivida obtained porous silicon technology from the British government Defence Evaluation and Research Agency (DERA, now QinetiQ).[citation needed] QinetiQ continues to be a strategic partner.[1][2]
In June 2004, pSivida acquired full ownership of pSiMedica.[1] In April 2018, pSivida purchased eye products firm Icon Bioscience.[3][4] Afterwards, it rebranded to its current name of EyepOint Pharmaceuticals, Inc.[5]
See also
edit- Alimera Sciences, pSvida's partner on Iluvien
References
edit- ^ a b "PSivida lifts pSiMedica stake to 100%". The Sydney Morning Herald. 2004-06-02. Retrieved 2020-10-29.
- ^ "Nano silicon boosts tumour fight". 2004-06-18. Retrieved 2020-10-29.
- ^ "BRIEF—pSivida to buy eye products firm Icon Bioscience". The Pharma Letter. Retrieved 2018-06-22.
- ^ "BRIEF-pSivida Corp Announces Transformative Acquisition Of Icon Bioscience". Reuters. 2018-03-28. Retrieved 2020-10-29.
- ^ "pSivida Corp. Announces Transformative Acquisition of Icon Bioscience Inc. and Growth Capital Financing with Essex Woodlands Healthcare Partners - Company Will Rebrand as EyePoint Pharmaceuticals, Inc". EyePoint Pharmaceuticals. March 28, 2018. Retrieved March 28, 2018.
External links
edit- Official website
- "pSivida (PSDV) Enters Two Funded Evaluation Agreements with Leading Pharma". StreetInsider.com. May 12, 2015. Retrieved May 15, 2015.
- Lindon, Hal (May 5, 2014). "UPDATE: pSivida Issues Presentation of Preclinical Data Showing Sustained Release of Avastin Using Tethadur". Benzinga. Retrieved May 15, 2015.
pSivida's Dinesh K. Nadarassan presented a poster entitled "Sustained Release of Bevacizumab (Avastin) from BioSilicon"
- pSivida Mesoporous silicon patent
 | This United States manufacturing company–related article is a stub. You can help Wikipedia by expanding it. |
 | This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it. |